Search 

MetalloBio are developing two novel antimicrobial leads to treat pathogenic, multi-drug resistant infections caused by Gram-negative bacteria. 

Oncimmune’s intimate understanding of the human immune system enables the Company to harness its sophisticated response to disease to detect cancer earlier and to support the development of better therapies.

The key to improving cancer survival is early detection and optimal selection for therapy. Oncimmune is driven by a passion to improve cancer survival and to give people extra time. Oncimmune's immuno-diagnostic test, EarlyCDT, can detect and help identify cancer on average four years earlier than standard clinical diagnosis.

The unique combination of our core technology and understanding of the immune system, powers our ImmunoINSIGHTS service; a proprietary platform that enables life-science organisations to optimise drug development and delivery, leading to more effective, targeted as well as safer treatments for patients.​

Oncimmune was founded in 2002 and launched its platform diagnostic technology in 2009, followed by the launch of its first commercial tests, EarlyCDT Lung and EarlyCDT Liver. To date, over 200,000 tests have been performed for patients worldwide. EarlyCDT Lung was also used in what is believed to be the largest randomised controlled trial for the early detection of lung cancer using biomarkers, the successful NHS Early detection of Cancer of the Lung (ECLS) trial of 12,209 high-risk smokers in Scotland. This trial demonstrated that EarlyCDT Lung reduced the incidence of patients with late-stage lung cancer or unclassified presentation at diagnosis, compared to standard clinical practice.

Headquartered at its laboratory facility in Nottingham, UK, Oncimmune has a discovery research centre in Dortmund, Germany and in London, UK and a partner representative office in Shanghai, China. Oncimmune joined the Alternative Investment Market (AIM) of the London Stock Exchange in May 2016 under the ticker ONC.L.

Oxford Biomedica (LSE: OXB) is a leading, fully integrated, cell and gene therapy group.

We have built a sector leading viral vector platform, including our lentiviral vector delivery system, LentiVector® platform, which we leverage to develop in vivo and ex vivo products both in-house and with partners. We have also created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, CNS disorders and liver diseases.

Building on our world leading position in lentiviral vectors and success in the adenovirus vector-based AstraZeneca COVID-19 vaccine, we have demonstrated the versatility of our platform and have extended our scope to all types of viral vectors.

Oxford Biomedica has a number of further partnerships, including with Novartis, Juno Therapeutics/ Bristol Myers Squibb, Boehringer Ingelheim, Beam Therapeutics, Arcellx, Cabaletta, Orchard Therapeutics and Santen.

Additionally, we have a three-year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine.

Oxford Biomedica is based across several locations and headquartered in Oxfordshire, UK. In early 2022, Oxford Biomedica announced that it was broadening its leading viral vector offerings by incorporating Homology Medicines’ established AAV capabilities into  a newly formed AAV Manufacturing and Innovation Business, Oxford Biomedica Solutions, based near Boston, Massachusetts, with Homology Medicines as a 20% owner.

We’re OxSonics, a pioneering clinical-stage therapeutics company committed to developing a ground-breaking platform technology to make anti-cancer drugs smarter, act faster and, above all, work better.

Our SonoTran® Platform has been designed to actively enhance the delivery of oncology drugs into solid tumours. SonoTran® is drug agnostic and requires no drug reformulation enabling its use with both existing and novel therapies.

We have our own development programs as well as collaborations with Pharmaceutical and biotech companies to work to bring smarter, faster and better therapies to as many patient groups as possible.

SomaServe's PolyNaut platform addresses the ‘delivery problem’. Reaching the site of action is one of the most pressing challenges in the advancement of gene therapy and the development of protein therapeutics for intracellular targets.

Using polyNaut technology we are uniquely able to address the shortcomings of viral or lipid-based delivery technologies by encapsulating a range of therapeutic modalities into polymer nanovesicles that can penetrate the blood brain barrier effectively and selectively target different tissues and cell types. 

Through partnerships we are deploying PolyNaut to develop a next generation of gene therapies and intracellular proteins in oncology, immunology and CNS disorders.